Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
